A practical reference on Dipeptidyl peptidase-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-13 and is reviewed periodically as new material appears.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
The Vietnamese were locked in a civil war over the destiny of their post-colonial state after the ousting of the French and the surrender of Japan in 1945. The communist-controlled Viet Minh sought to consolidate power by terrorizing and purging rival Vietnamese nationalist groups amid the French reconquest. Tensions between the Viet Minh, led by Ho Chi Minh, and the French erupted into the First Indochina War in December 1946. From early on, the Vietnamese communists were deeply committed to a radical ideology, occasionally harboring ambitions to lead the world revolution. In 1949, Mao's communists took control of the north side of the China–Vietnam border, and began supporting the Democratic Republic of Viet Nam (DRV). Mark Lawrence and Frederik Logevall point out that "resurgent French colonialism became inextricably intertwined with Cold War tensions, especially in the years after 1949". American pressure on France after 1949 tried to force France to give priority to fighting communism, rather than fighting Vietnamese nationalism. The nationalist State of Vietnam (SVN), with Bảo Đại as Chief of State, was established and positioned within the anticommunist Western Bloc. With the recognition of the DRV by communist China and the Soviet Union, and the recognition of the SVN by the United States in 1950, the civil war and the colonial war in Vietnam became internationalized and intertwined with the global Cold War.
== Development == The aldehyde tag is an artificial peptide tag recognized by the formylglycine-generating enzyme (FGE). Formylglycine is a glycine with a formyl group (-CHO) at the α-carbon. The sulfatase motif is the basis for the sequence of the peptide which results in the site-specific conversion of a cysteine to a formylglycine residue. The peptide tag was engineered after studies on FGE recognizable sequences in sulfatases from different organisms revealed a high homology in the sulfatase motif in bacteria, archaea as well as eukaryotes. Aldehydes and ketones are used as chemical reporters due to their electrophilic properties. These properties enable a reaction under mild conditions when using a strong nucleophilic coupling partner. Typically, hydrazides and aminooxy probes are used in bioconjugation by forming stabilized addition products with carbonyl groups that are favored under the physiological reaction conditions. At neutral pH, the equilibrium of Schiff base formation lies far to the reactant side. To form stable hydrazones and oximes, compound derivatives are used to yield more product. Since the pH optimum of 4 to 6 cannot be achieved by adding a catalyst due to associated toxicity, the reaction is slow in live cells. A typical reaction constant is 10−4 to 10−3 M−1 s−1. A carbonyl group is introduced into proteins as a chemical reporter using various techniques, including methods like stop codon suppression and aldehyde tagging. Limiting the use of aldehydes and ketones is their restricted bioorthogonality in certain cellular environments.
=== Electricity and Wi-Fi === In August 2002, Starbucks provided free Wi-Fi in the United Kingdom, although in the past, a Starbucks rewards card was required. On July 1, 2010, Starbucks offered free Wi-Fi in all of its stores in the U.S. and Canada. In August 2010, Starbucks began offering free Wi-Fi in Germany via BT Openzone. In October 2012, Starbucks and Duracell Powermat announced a pilot program to install Powermat charging surfaces in the tabletops in selected Starbucks stores in the Boston area. Furthermore, Starbucks announced its support in the Power Matters Alliance (PMA) and its membership in the PMA board, along with Google and AT&T, in an effort to create "a real-world ecosystem of wireless power" through a universal wireless charging standard that customers could use to recharge smartphones. In 2013, it switched providers in the U.S. from AT&T to Google. In August 2016, startup company FluxPort introduced Qi inductive charging pads at select locations in Germany.
=== Awards and honours === Winner of the CA/Zurich Business Leader Award in 2002 Winner of the inaugural Trans-Tasman Business Leader Award in 2005 Awarded a Doctor of Business honoris causa by RMIT University in 2008 Appointed Officer of the Order of Australia (AO) in 2010 for service to the development of the transport and logistics industries through strategic leadership and promotion of corporate social and environmental responsibility, and to the community through philanthropic support of sporting and medical research organisations. Little is also a Fellow of the Australian Institute of Company Directors and a Fellow of the Chartered Institute of Logistics and Transport (FCILT).
=== Eyes === Tacrolimus solution, as drops, is sometimes prescribed by veterinarians for keratoconjunctivitis, and other dry eye maladies, in the eyes of domestic cats, dogs, and horses. It has been studied for use in human eyes.
Sources: en.wikipedia.org
4-nitrophenol 4-monooxygenase (EC 1.14.13.167, pnpA (gene), pdcA (gene)) is an enzyme with systematic name 4-nitrophenol,NAD(P)H:oxygen 4-oxidoreductase (4-hydroxylating, nitrite-forming). This enzyme catalyses the following chemical reaction
Natural viral diseases, such as myxomatosis and rabbit hemorrhagic disease, have been used to help control pest populations. Over time the surviving pests become resistant, leading researchers to look at alternative methods. Genetically modified viruses that make the target animals infertile through immunocontraception have been created in the laboratory as well as others that target the developmental stage of the animal. There are concerns with using this approach regarding virus containment and cross species infection. Sometimes the same virus can be modified for contrasting purposes. Genetic modification of the myxoma virus has been proposed to conserve European wild rabbits in the Iberian peninsula and to help regulate them in Australia. To protect the Iberian species from viral diseases, the myxoma virus was genetically modified to immunize the rabbits, while in Australia the same myxoma virus was genetically modified to lower fertility in the Australian rabbit population. Outside of biology scientists have used a genetically modified virus to construct a lithium-ion battery and other nanostructured materials. It is possible to engineer bacteriophages to express modified proteins on their surface and join them up in specific patterns (a technique called phage display). These structures have potential uses for energy storage and generation, biosensing and tissue regeneration with some new materials currently produced including quantum dots, liquid crystals, nanorings and nanofibres.
Psilocybin has been a subject of clinical research since the early 1960s, when the Harvard Psilocybin Project evaluated the potential value of psilocybin as a treatment for certain personality disorders. The similarity of psilocybin-induced symptoms to those of schizophrenia has made the drug a useful research tool in behavioral and neuroimaging studies of schizophrenia. In both cases, psychotic symptoms are thought to arise from a "deficient gating of sensory and cognitive information" in the brain that leads to "cognitive fragmentation and psychosis". Since the 2000s, psilocybin has been investigated for its possible role in the treatment of nicotine dependence, alcohol dependence, obsessive–compulsive disorder (OCD), cluster headache, cancer-related existential distress, anxiety disorders, and certain mood disorders. It is also being studied in people with Parkinson's disease. In 2018, the US Food and Drug Administration (FDA) granted breakthrough therapy designation for psilocybin-assisted therapy for treatment-resistant depression. The role of psilocybin as a possible psychoplastogen is also being examined. It is under development by Compass Pathways, Cybin, and other companies.
=== TruB === The TruB family only contains PUS 4 located in the mitochondrion and nucleus. PUS 4 modification is heavily conserved located in the U55 in the elbow of the tRNA. The human form of PUS 4 is actually missing a binding domain called PUA or pseudouridine synthase and archaeosine trans-glycosylase. PUS 4 has a sequence specificity for T-loop part of the tRNA. Preliminary data of PUS4 modifying mRNA, but more research is needed to confirm. Also binds to a specific Brome Mosaic Virus, which is a plant-infecting RNA virus.
{\displaystyle {\boldsymbol {\sigma }}(\mathbf {u} ,p){\hat {\mathbf {n} }}={\bigl (}-p\mathbf {I} +2\mu {\boldsymbol {\varepsilon }}(\mathbf {u} ){\bigr )}{\hat {\mathbf {n} }}=-p{\hat {\mathbf {n} }}+\mu {\frac {\partial {\boldsymbol {u}}}{\partial {\hat {\mathbf {n} }}}}.}
Sources: en.wikipedia.org
On 7 December 2024, Syrian rebels announced that they had started surrounding Damascus after capturing nearby towns, with rebel commander Hassan Abdul Ghani stating: "Our forces have begun implementing the final phase of encircling the capital Damascus." The rebels started encircling the capital after capturing Al-Sanamayn, a town 20 kilometres (12 mi) from the southern entrance of Damascus. In the Rif Dimashq region, pro-government forces withdrew from the towns of Assal al-Ward, Yabroud, Flitah, Al-Naseriyah and Artouz, while rebels came within 10 kilometres (6.2 mi) of Damascus. The Syrian government denied claims that its army had withdrawn from positions near the city. By the evening, pro-government forces had left the towns on the outskirts of Damascus, including Jaramana, Qatana, Muadamiyat al-Sham, Darayya, Al-Kiswah, Al-Dumayr, Daraa and sites near the Mezzeh Air Base. Maher al-Assad and his 4th Division were reportedly among the few loyalists who still tried to defend the city; his second-in-command was later found dead in his office, possibly indicating violent disputes over the orders and escapes of many military officers. According to the Syrian Observatory for Human Rights, Syrian rebels were active in the Damascus suburbs of Jaramana, Muadamiyah, and Darayya, and were marching from the east toward Harasta. In the main square of Jaramana, protestors took down a statue of Hafez al-Assad. In the evening, pro-government forces reportedly withdrew from several suburbs where large-scale protests broke out.
== Clinical Evidence & Applications == Clinical and research studies suggest ZnC supports intestinal barrier function and may reduce inflammation in conditions like ulcerative colitis. Human and animal studies demonstrate mucosal protection against chemical injury and improved reparative responses. Reviews of clinical studies show benefit in oral and esophageal mucositis in cancer patients receiving chemoradiation, attributed to epithelial protection. Evidence supports the safety and efficacy of ZnC for the maintenance, prevention, and treatment of the mucosal lining and other epithelial tissues. The research supports its use for gastric ulcers and conditions of the upper GI and suggests other applications, particularly for oral mucositis.
Traditionally used packaging films like LDPE (low-density polyethylene), PVC (polyvinyl chloride), EVA (ethylene-vinyl acetate) and OPP (oriented polypropylene) are not permeable enough for highly respiring products like fresh-cut produce, mushrooms and broccoli. As fruits and vegetables are respiring products, there is a need to transmit gases through the film. Films designed with these properties are called permeable films. Other films, called barrier films, are designed to prevent the exchange of gases and are mainly used with non-respiring products like meat and fish. MAP films developed to control the humidity level as well as the gas composition in the sealed package are beneficial for the prolonged storage of fresh fruits, vegetables and herbs that are sensitive to moisture. These films are commonly referred to as modified atmosphere/modified humidity packaging (MA/MH) films.
Similarly to other classic psychedelics, DET acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. The drug has been shown to activate Gq-mediated signaling at the serotonin 5-HT2A receptor with Emax higher than 70% and to produce the head-twitch response in rodents which is a behavioral proxy of psychedelic-like effects. It is also a serotonin receptor agonist in the rat uterus and stomach strip, with slightly greater potency than dimethyltryptamine (DMT). DET is a very weak reversible monoamine oxidase inhibitor (MAOI), with IC50Tooltip half-maximal inhibitory concentration values of 59 μM for serotonin and 5,000 μM for tryptamine as substrates. Injections of 30 mg/kg to rats resulted in 67% reduction of brain MAO-A activity 15 minutes after administration. The substance may also act as a serotonin reuptake inhibitor, with low affinity but moderate potency. It shows no activity as a norepinephrine or dopamine reuptake inhibitor.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.